Home ›
NPI 1619925633
NPI deactivated
1619925633
1619925633 was paid $484K by Medicaid between Jan 2018 and Dec 2020, across 27 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 28% of everything it billed.
33Billing provider info1619925633
33aNPI1619925633
33bProvider type—
28Total paid$484K
24GClaims19,372
24DCodes billed27
24AFirst – last monthJan 2018 – Dec 2020
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,509 | $180K | |
| 2019 | 7,053 | $169K | |
| 2020 | 5,810 | $135K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 28% | 2,294 | 2,103 | $138K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 24% | 1,323 | 1,233 | $119K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 7.4% | 1,695 | 1,678 | $36K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.4% | 371 | 371 | $31K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 4.4% | 229 | 229 | $21K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.9% | 839 | 788 | $14K |
| S0302 | Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) | 2.9% | 1,524 | 1,520 | $14K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.8% | 174 | 157 | $13K |
| 96127 | 2.8% | 1,231 | 1,207 | $13K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.7% | 1,537 | 1,433 | $13K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 2.7% | 965 | 906 | $13K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 2.2% | 128 | 128 | $11K |
15 more codes
| 90472 | Immunization administration, each additional vaccine (list separately) | 1.8% | 589 | $9K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 258 | $7K |
| A4258 | Spring-powered device for lancet, each | 1.2% | 1,520 | $6K |
| 36416 | 1.2% | 597 | $6K | |
| 87081 | 1.1% | 778 | $5K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 365 | $4K |
| 92550 | <1% | 170 | $3K | |
| 94760 | <1% | 969 | $2K | |
| 87070 | <1% | 98 | $2K | |
| A7004 | Small volume nonfiltered pneumatic nebulizer, disposable | <1% | 894 | $1K |
| 92552 | <1% | 64 | $1K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 13 | $1K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 12 | $412.20 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 235 | $327.39 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 500 | $189.80 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.